Evidence map›Paper›PMID 29093663›Full record

ArticleFrontiers in molecular neuroscience2017

Selection and Characterization of Palmitic Acid Responsive Patients with an OXPHOS Complex I Defect.

Tom E J Theunissen, Mike Gerards, Debby M E I Hellebrekers, Florence H van Tienen, Rick Kamps, Suzanne C E H Sallevelt, Elvira N M M-D Hartog, Hans R Scholte, Robert M Verdijk, Kees Schoonderwoerd and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in molecular neuroscience, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Tom E J TheunissenDepartment of Clinical Genetics, Maastricht University Medical Centre, Maastricht, Netherlands.
Mike GerardsMaastricht Centre for Systems Biology, Maastricht University, Maastricht, Netherlands.
Debby M E I HellebrekersDepartment of Clinical Genetics, Maastricht University Medical Centre, Maastricht, Netherlands.
Florence H van TienenDepartment of Clinical Genetics, Maastricht University Medical Centre, Maastricht, Netherlands.
Rick KampsDepartment of Clinical Genetics, Maastricht University Medical Centre, Maastricht, Netherlands.
Suzanne C E H SalleveltDepartment of Clinical Genetics, Maastricht University Medical Centre, Maastricht, Netherlands.
Elvira N M M-D HartogDepartment of Neurology, Erasmus Medical Center, Rotterdam, Netherlands.
Hans R ScholteDepartment of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands.
Robert M VerdijkDepartment of Pathology, Erasmus Medical Center, Rotterdam, Netherlands.
Kees SchoonderwoerdDepartment of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands.
Irenaeus F M de CooDepartment of Neurology, Erasmus Medical Center, Rotterdam, Netherlands.
Radek SzklarczykDepartment of Clinical Genetics, Maastricht University Medical Centre, Maastricht, Netherlands.
Hubert J M SmeetsDepartment of Clinical Genetics, Maastricht University Medical Centre, Maastricht, Netherlands.
Maastricht University Medical Centre · NLErasmus MC · NLMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mitochondrial disorders are genetically and clinically heterogeneous, mainly affecting high energy-demanding organs due to impaired oxidative phosphorylation (OXPHOS). Currently, effective treatments for OXPHOS defects, with complex I deficiency being the most prevalent, are not available. Yet, clinical practice has shown that some complex I deficient patients benefit from a high-fat or ketogenic diet, but it is unclear how these therapeutic diets influence mitochondrial function and more importantly, which complex I patients could benefit from such treatment. Dietary studies in a complex I deficient patient with exercise intolerance showed increased muscle endurance on a high-fat diet compared to a high-carbohydrate diet. We performed whole-exome sequencing to characterize the genetic defect. A pathogenic homozygous p.G212V missense mutation was identified in the

Indexed as

assembly factorscomplex I deficiencyhigh-fat dietpalmitic acidTMEM126B

Identifiers

PMID29093663
PMCPMC5651253
OpenAlexW2766841466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.